Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Working Capital Changes (2016 - 2025)

Ligand Pharmaceuticals' Other Working Capital Changes history spans 16 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 2004.2% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $1.7 million, up 230.75%, while the annual FY2025 figure was $1.7 million, 230.75% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.3 million at Ligand Pharmaceuticals, up from -$285000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $10.6 million in Q2 2021 and bottomed at -$23.8 million in Q4 2021.
  • The 5-year median for Other Working Capital Changes is -$232000.0 (2024), against an average of -$1.2 million.
  • The largest annual shift saw Other Working Capital Changes tumbled 445.64% in 2022 before it surged 2004.2% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$23.8 million in 2021, then soared by 73.51% to -$6.3 million in 2022, then surged by 108.15% to $513000.0 in 2023, then tumbled by 123.2% to -$119000.0 in 2024, then soared by 2004.2% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Working Capital Changes are $2.3 million (Q4 2025), -$285000.0 (Q2 2025), and -$293000.0 (Q1 2025).